Top Markets
Coin of the day
Acticor Biotech SAS Acticor Biotech SAS

Acticor Biotech SAS

ALACT
Rankning i aktier #37014
Acticor Biotech SAS is a clinical-stage biotechnology firm focused on creating... Acticor Biotech SAS is a clinical-stage biotechnology firm focused on creating therapies for the acute phase of thrombotic conditions. The company's lead compound, glenzocimab, is a humanized monoclonal antibody fragment specifically designed to target a particular platelet glycoprotein. Currently, Acticor Biotech is advancing two clinical programs, both in Phase II/III, for the registration of treatments for ischemic stroke. Additionally, it is conducting two other Phase II trials concerning significant cardiovascular emergencies, with anticipated clinical data expected from both its ischemic stroke research and studies related to COVID-19 respiratory distress syndrome. Established in 2013, the company operates from its headquarters in Paris, France.
Aktiekurs
$0.25974701
Senast synkroniserad: 2025-01-06
Marknadsvärde
$2.04M
Förändring (1 dag)
0.74%
Förändring (1 år)
0.00%
Land
FR
Handel Acticor Biotech SAS (ALACT)

Kategori

EPS för Acticor Biotech SAS (ALACT)
EPS per June 2024 TTM: $-1.95
Enligt Acticor Biotech SASs senaste finansiella rapporter och aktiekurs är bolagets nuvarande EPS (TTM) $-1.95. Vid slutet av 2022 hade bolaget ett EPS på $-1.62, en minskning jämfört med EPS från 2021 som var $-1.84.
EPS-historik för Acticor Biotech SAS från 2010 till 2026
EPS vid slutet av varje år
År EPS Ändra
2026 (TTM) $-1.95 -99.90%
2023 0.00 -99.90%
2022 $-1.62 -12.08%
2021 $-1.84 26.05%
2020 $-1.46 35.69%
2019 $-1.08 -51.93%
2018 $-2.24 -40.33%
2017 $-3.76 2,449.69%
2016 $-0.15 -66.91%
2015 $-0.45 26.87%
2014 $-0.35 -143.25%
2013 $0.81 -9.55%
2012 $0.90 35.87%
2011 $0.66 462.35%
2010 $0.12 0.00%
EPS för liknande företag eller konkurrenter
Företag EPS EPS-differens Land
$17.32 -986.39%
US
$27.74 -1,519.65%
NL
$-5.29 170.73%
AU
$-7.98 308.39%
US
- -
CH